- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| Do | Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program | 1 | GlobeNewswire (USA) | ||
| 29.01. | Longeveron Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) | 1 | GlobeNewswire (USA) | ||
| 26.01. | Longeveron prepares for pivotal HLHS therapy data with FDA meeting | 1 | Investing.com | ||
| 26.01. | Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) | 181 | GlobeNewswire (Europe) | ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS... ► Artikel lesen | |
| 29.12.25 | Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 | 5 | GlobeNewswire (USA) | ||
| 17.12.25 | Longeveron receives patent for stem cell therapy targeting female sexual dysfunction | 3 | Investing.com | ||
| 17.12.25 | Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy | 1 | GlobeNewswire (USA) | ||
| 03.12.25 | Longeveron executives to speak at CVCT Forum on cell therapy trials | 1 | Investing.com | ||
| 03.12.25 | Longeveron: Führungskräfte präsentieren auf Fachforum für Zelltherapie-Studien | 1 | Investing.com Deutsch | ||
| 03.12.25 | Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Longeveron erhält kanadisches Patent für Stammzelltherapie | 1 | Investing.com Deutsch | ||
| 02.12.25 | Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging | 2 | GlobeNewswire (USA) | ||
| 01.12.25 | Longeveron's stem cell therapy shows reduced neuroinflammation in AD trial | 3 | Investing.com | ||
| 19.11.25 | Longeveron stellt Daten zur Alzheimer-Therapie auf der CTAD 2025 vor | 2 | Investing.com Deutsch | ||
| 19.11.25 | Longeveron to present Alzheimer's treatment data at CTAD 2025 | 1 | Investing.com | ||
| 12.11.25 | Longeveron secures patent for stem cell therapy targeting aging frailty | 2 | Investing.com | ||
| 12.11.25 | Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy | 451 | GlobeNewswire (Europe) | The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved... ► Artikel lesen | |
| 12.11.25 | Longeveron: Zwei Vorstandsmitglieder legen Ämter nieder | 4 | Investing.com Deutsch | ||
| 12.11.25 | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.11.25 | Longeveron GAAP EPS of -$0.39 misses by $0.13, revenue of $125M beats by $124.71M | 2 | Seeking Alpha |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 41,200 | -0,48 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| OCUGEN | 1,150 | +1,05 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen | |
| EDITAS MEDICINE | 1,536 | +0,03 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,568 | +2,10 % | PacBio Completes Sale of Short-Read Sequencing Assets | MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of... ► Artikel lesen | |
| CYTODYN | 0,195 | 0,00 % | CytoDyn Inc.: December 2025 Letter to Shareholders | VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your... ► Artikel lesen | |
| DENALI THERAPEUTICS | 17,655 | -0,93 % | Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement | WASHINGTON (dpa-AFX) - Denali Therapeutics Inc. (DNLI) and Royalty Pharma plc (RPRX) on Thursday announced a $275 million synthetic royalty funding agreement tied to future net sales of Tividenofusp... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,060 | -5,35 % | SOL Global Investments Corp.: SOL Global Announces Settlement of Outstanding Debentures | Toronto, Ontario--(Newsfile Corp. - January 21, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCD) (FSE: 9SB0) ("SOL" or the "Company") is pleased to announce that it has satisfied its... ► Artikel lesen | |
| TRINITY BIOTECH | 0,786 | +11,14 % | Trinity Biotech plc: Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives | - Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 - Equity settlement mechanisms also agreed for milestone payments and contingent acquisition... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,928 | -3,35 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| VOYAGER THERAPEUTICS | 3,126 | +0,51 % | Voyager Therapeutics, Inc.: Voyager Reports Third Quarter 2025 Financial and Operating Results | - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle discovery... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 3,617 | +4,15 % | ANAVEX LIFE SCIENCES CORP kurz vor dem entscheidenden Ausbruch | ||
| ARCTURUS THERAPEUTICS | 7,560 | +7,69 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| BIOAGE LABS | 16,600 | -5,68 % | AKTIONÄR-Tipp BioAge Labs wird entdeckt: 272 Prozent Kurspotenzial! | Der Megatrend Longevity hat nun auch die Aktie von BioAge Labs erfasst. Ausgehend vom 52-Wochen-Tief bei 2,88 Dollar konnte sich der Titel auf aktuell 19,60 Dollar zuletzt vervielfachen. Und die Analysten... ► Artikel lesen | |
| CERUS | 1,852 | -0,75 % | Cerus Corporation: DRK Blood Donation Service Baden-Württemberg - Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT Blood System in Routine Clinical Practice | Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg Hessen and its subsidiary organization, the German... ► Artikel lesen | |
| LINEAGE CELL THERAPEUTICS | 1,430 | -0,69 % | Regenerative Medizin auf dem Vormarsch: Exosomen, Gen- und Zelltherapien als Wegbereiter neuer Heilansätze |
LONGEVERON INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,513 Euro und damit +0,39 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.